Patents by Inventor Harald Potzschke

Harald Potzschke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11116868
    Abstract: The present invention refers to a composition, comprising hemoglobin or myoglobin, wherein in at least 40% of said hemoglobin or myoglobin the oxygen binding site is charged by a non-O2 ligand, and at least one further ingredient, a method for preparing said composition and the use of hemoglobin or myoglobin charged with a non-oxygen ligand for external treatment of wounds.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: September 14, 2021
    Assignee: MÖLNLYCKE HEALTH CARE AB
    Inventors: Michael Sander, Harald Potzschke
  • Publication number: 20200230285
    Abstract: The present invention refers to a composition, comprising hemoglobin or myoglobin, wherein in at least 40% of said hemoglobin or myoglobin the oxygen binding site is charged by a non-O2 ligand, and at least one further ingredient, a method for preparing said composition and the use of hemoglobin or myoglobin charged with a non-oxygen ligand for external treatment of wounds.
    Type: Application
    Filed: March 31, 2020
    Publication date: July 23, 2020
    Applicant: MÖLNLYCKE HEALTH CARE AB
    Inventors: Michael Sander, Harald Potzschke
  • Patent number: 10646613
    Abstract: The present invention refers to a composition, comprising hemoglobin or myoglobin, wherein in at least 40% of said hemoglobin or myoglobin the oxygen binding site is charged by a non-O2 ligand, and at least one further ingredient, a method for preparing said composition and the use of hemoglobin or myoglobin charged with a non-oxygen ligand for external treatment of wounds.
    Type: Grant
    Filed: July 23, 2012
    Date of Patent: May 12, 2020
    Assignee: MÖLNLYCKE HEALTH CARE AB
    Inventors: Michael Sander, Harald Potzschke
  • Patent number: 10471175
    Abstract: A method for preparing a composition for external treatment of wounds includes charging at least 90% of the oxygen binding sites of hemoglobin with carbon monoxide during or after isolation from its natural environment. The method further includes adding at least one further ingredient selected from the group consisting of electrolyte(s), preservative(s), stabilizer(s), anti-flocculant(s), anticoagulant(s), pH buffering agent(s), solvent(s), antioxidant(s), film-forming agent(s) and crosslinking agent(s). The method can further include packaging the composition, such as in an aerosol can.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: November 12, 2019
    Assignee: MÖLNLYCKE HEALTH CARE AB
    Inventors: Michael Sander, Harald Potzschke
  • Publication number: 20160228602
    Abstract: A method for preparing a composition for external treatment of wounds includes charging at least 90% of the oxygen binding sites of hemoglobin with carbon monoxide during or after isolation from its natural environment. The method further includes adding at least one further ingredient selected from the group consisting of electrolyte(s), preservative(s), stabilizer(s), anti-flocculant(s), anticoagulant(s), pH buffering agent(s), solvent(s), antioxidant(s), film-forming agent(s) and crosslinking agent(s). The method can further include packaging the composition, such as in an aerosol can.
    Type: Application
    Filed: April 21, 2016
    Publication date: August 11, 2016
    Inventors: Michael Sander, Harald Potzschke
  • Publication number: 20140221944
    Abstract: The present invention refers to a composition, comprising hemoglobin or myoglobin, wherein in at least 40% of said hemoglobin or myoglobin the oxygen binding site is charged by a non-O2 ligand, and at least one further ingredient, a method for preparing said composition and the use of hemoglobin or myoglobin charged with a non-oxygen ligand for external treatment of wounds.
    Type: Application
    Filed: July 23, 2012
    Publication date: August 7, 2014
    Applicant: SastoMed GmbH
    Inventors: Michael Sander, Harald Potzschke
  • Patent number: 7005414
    Abstract: According to the claims, the present invention comprises the preparation of chemically modified, cross-linked hemoglobins with improved functional properties, the cross-linked hemoglobins prepared according to this method and the use of these hemoglobins as artificial oxygen carriers. The synthesis method is characterized by technical simplicity as well as by high yields. Deoxygenated hemoglobin of high purity is conjugated covalently under the protection of an antioxidant with an effector of oxygen binding, especially with pyridoxal-5-phosphate, after which the hemoglobin is polymerized with glutardialdehyde as a bifunctional cross-linking agent. At the same time, there is a large increase in the volume of the reaction mixture and a decrease in the concentration of the hemoglobin during the addition of the cross-linking agent. Subsequently, after further dilution with water, a polyethylene oxide derivative is chemically linked to the cross-linked hemoglobins.
    Type: Grant
    Filed: June 12, 2001
    Date of Patent: February 28, 2006
    Assignee: Sanguibiotech GmbH
    Inventors: Wolfgang Barnikol, Oswald Burkhard, Harald Pötzschke, Ulrike Domack, Stephanie Dinkelmann, Bernd Fiedler, Birgit Manz
  • Publication number: 20040029780
    Abstract: According to the claims, the present invention comprises the preparation of chemically modified, cross-linked hemoglobins with improved functional properties, the cross-linked hemoglobins prepared according to this method and the use of these hemoglobins as artificial oxygen carriers. The synthesis method is characterized by technical simplicity as well as by high yields.
    Type: Application
    Filed: August 28, 2003
    Publication date: February 12, 2004
    Inventors: Wolfgang Barnikol, Oswald Burkhard, Harald Potzschke, Ulrike Domack, Stephanie Dinkelmann, Bernd Fiedler, Birgit Manz
  • Publication number: 20030147078
    Abstract: The invention relates to a method for the long-term stable and well-reproducible spectrometric measurement of the concentrations of components of aqueous solutions, especially of dialysates of interstitial tissue fluids, especially the glucose concentration. The inventive method comprises splitting a measuring beam into two partial beams by means of a beam splitter (2), and guiding one partial beam through a measuring cuvette (3), that is separated from the solution to be measured for example by a diaphragm, or that is connected to a pump system with an exchange path that is separated from the solution to be measured by a diaphragm. The other partial beam is guided through a reference cuvette (4) that is filled with a reference solution. The light intensity of both partial beams is measured and the measured signals are subjected to a symmetrical signal processing, optionally after suitable amplification.
    Type: Application
    Filed: April 7, 2003
    Publication date: August 7, 2003
    Inventors: Kai-Uwe Zirk, Harald Potzschke
  • Patent number: 6577393
    Abstract: In a process or device for very accurate determination of the plane of polarization of polarized light, the light from a light source (1) is polarized by means of a polarizing filter (2) which has a certain setting angle &thgr;0 with respect to the first reference plane, the plane of incidence on the reflecting surface (4). The polarized beam (12) passes through the sample in the measurement chamber (3), in which the angle of rotation is changed by the small angle &thgr;MG. The sum of &thgr;0 and &thgr;MG gives the angle of rotation &thgr;e , at which the beam (13) emerging from the measurement chamber is partially reflected at the surface of a medium of higher refractive index (4).
    Type: Grant
    Filed: March 23, 2001
    Date of Patent: June 10, 2003
    Assignee: Glukomeditech AB
    Inventors: Harald Pötzschke, Wolfgang Barnikol, Kai Zirk
  • Patent number: 5985332
    Abstract: Artificial oxygen carrier composed of native or modified hemoglobins for direct biological or medical use, in which the oxygen binding site of the hemoglobin is provided with a protective ligand, preferably carbon monoxide, which does not have to be removed prior to use.
    Type: Grant
    Filed: January 9, 1998
    Date of Patent: November 16, 1999
    Assignee: Sanguibiotech AG
    Inventors: Wolfgang Barnikol, Harald Potzschke